Entera Bio (NASDAQ:ENTX) Trading Down 0.6% – Here’s Why

Entera Bio Ltd. (NASDAQ:ENTX) dropped 0.6% on Wednesday . The company traded as low as $1.45 and last traded at $1.54. 610,262 shares changed hands during mid-day trading, a decline of 78% from the average daily volume of 2,768,290 shares. The stock had previously closed at $1.55.

Analyst Ratings Changes

A number of research analysts recently commented on the company. HC Wainwright reissued a “buy” rating on shares of Entera Bio in a report on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Entera Bio in a report on Tuesday, April 21st. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $9.00.

Entera Bio Stock Up 13.9%

The company has a market capitalization of $81.38 million, a P/E ratio of -6.11 and a beta of 1.56. The business has a 50 day moving average of $1.25 and a 200 day moving average of $1.41.

Entera Bio (NASDAQ:ENTX) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. On average, research analysts anticipate that Entera Bio Ltd. will post -0.34 EPS for the current year.

Institutional Investors Weigh In On Entera Bio

A number of hedge funds have recently bought and sold shares of the business. Superstring Capital Management LP purchased a new position in shares of Entera Bio in the 4th quarter worth $33,000. Renaissance Technologies LLC increased its holdings in shares of Entera Bio by 22.2% in the 4th quarter. Renaissance Technologies LLC now owns 108,001 shares of the company’s stock worth $210,000 after buying an additional 19,601 shares during the last quarter. HighTower Advisors LLC raised its position in shares of Entera Bio by 137.8% during the 4th quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock valued at $84,000 after buying an additional 25,000 shares in the last quarter. Citadel Advisors LLC lifted its holdings in shares of Entera Bio by 243.0% in the 3rd quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock valued at $77,000 after acquiring an additional 28,322 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC grew its position in Entera Bio by 5.2% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 596,585 shares of the company’s stock worth $1,157,000 after acquiring an additional 29,629 shares in the last quarter. Hedge funds and other institutional investors own 14.11% of the company’s stock.

About Entera Bio

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.